Plain-English translation of NCT06315010 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for people with a specific type of non-small cell lung cancer that has a ROS1 gene change and has spread to the brain. The study will look at how well this medication works in shrinking or controlling brain tumors. About 20 people will participate in this international study.
Brain metastases from lung cancer are difficult to treat and often have limited treatment options. This medication is designed to work specifically against the ROS1 genetic mutation and may be able to penetrate into the brain better than other treatments, potentially offering hope for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would take the medication as a capsule by mouth—starting with one dose daily for 14 days, then twice daily after that. You'll continue treatment until your disease progresses or you experience unacceptable side effects. The study includes regular clinic visits for blood work, brain imaging (MRI scans), and check-ups. After you stop taking the medication, you'll have a follow-up visit 28 days later, and researchers will check on your health and any new treatments you receive every three months for the rest of the study (estimated to last about 13 months total after the last patient joins).
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Austria
Germany
Spain